This biweekly Gene and Cell Therapy video recap highlights regulatory developments, clinical trial milestones, commercialization progress, and evolving evidence requirements across genetic medicines and advanced cellular therapies.
🎯 Watch Our Video Summary Capturing Cell and Gene Therapy News from the Last Two Weeks
🗓️ Explore details and sources
- Week 19–25 February 2026
- Week 25 February–4 March 2026
📚 See the full Cell and Gene Therapy archive on our research hub page.
Top Stories Covered in This Video
Chapters
0:00 Introduction
0:09 FDA outlines “plausible mechanism” pathway for bespoke genetic medicines
0:41 Ultragenyx DTX401 BLA accepted with Priority Review for GSDIa
1:20 Sarepta ELEVIDYS launches commercially in Japan via Chugai
1:50 Iovance lifileucel shows early activity in soft tissue sarcomas (UPS, DDLPS)
2:22 GEMMABio doses first patient in CHARISMA (GB221) for SMA1
2:55 uniQure AMT-130: FDA requests a randomized, sham-controlled study for Huntington’s
3:26 Ocugen completes Phase 3 liMeliGhT enrollment for OCU400 in retinitis pigmentosa
4:05 Intellia MAGNITUDE Phase 3 in ATTR-CM resumes after FDA hold lift
4:40 How to reach us
Transcript
Welcome to the latest edition of Gene and Cell Therapy Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.
The FDA outlined draft guidance describing a proposed “plausible mechanism” pathway for bespoke genetic medicines. The framework focuses on genome editing and RNA-based approaches for rare diseases and may allow approvals based on small patient numbers when supported by strong mechanistic evidence. The agency also noted that natural history data and post market evidence collection could support regulatory decisions under this model.
Ultragenyx announced that the FDA accepted its biologics license application for DTX401, also known as pariglasgene brecaparvovec, for glycogen storage disease type Ia. The application received Priority Review, and the FDA set a PDUFA action date of 23 August 2026. The submission is supported by a clinical program involving 52 treated patients with follow up of up to six years and includes data from the randomized, double blind, placebo controlled Phase 3 GlucoGene study.
Sarepta Therapeutics announced the commercial launch of ELEVIDYS in Japan through its partner Chugai, part of the Roche Group. The launch followed listing on Japan’s national health insurance price list. The therapy is indicated for ambulatory Duchenne muscular dystrophy patients aged three to less than eight years with specific exon eight or nine deletions and negative anti AAVrh74 antibody status.
Iovance reported early clinical activity for its tumor infiltrating lymphocyte therapy lifileucel in advanced soft tissue sarcomas. In a pilot trial led by Memorial Sloan Kettering Cancer Center, the therapy achieved an objective response rate of 50 percent in the first six evaluable patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma who had received at least one prior systemic therapy.
GEMMABio announced that the first patient has been dosed in the Phase one and two CHARISMA trial evaluating GB221 for spinal muscular atrophy type one. The study includes both symptomatic and presymptomatic pediatric participants between two weeks and less than twelve months of age and uses intracisterna magna delivery into the cerebrospinal fluid. The company also reported that the FDA granted rare pediatric disease designation for GB221.
uniQure provided a regulatory update on its AMT 130 gene therapy program for Huntington’s disease following a Type A meeting with the FDA. The agency indicated that Phase one and two data compared with an external control would not be sufficient as primary evidence for a marketing application and strongly recommended conducting a prospective randomized, double blind study with a sham surgery control.
Ocugen announced completion of enrollment in its Phase three liMeliGhT trial evaluating OCU400 for retinitis pigmentosa. The study enrolled 140 patients randomized two to one and is assessing a twelve month change in visual function measured using Lux level change as the primary endpoint. The company expects to report topline Phase three results in the first quarter of 2027 and noted that the EMA indicated the US based study could be acceptable for a future marketing authorization application.
Intellia Therapeutics reported that the FDA lifted the clinical hold on the investigational new drug application for the MAGNITUDE Phase three trial of nexiguran ziclumeran in transthyretin amyloid cardiomyopathy. The hold had been imposed after a liver safety signal in October 2025. The study will resume enrollment with updated safety measures including enhanced liver monitoring, short term steroid guidance, and additional exclusion criteria related to liver abnormalities and cardiovascular instability.
Stay ahead in Gene and Cell Therapy research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!
Why It Matters
- FDA’s proposed bespoke pathway, if finalized, could reshape evidence expectations for ultra-rare, mechanism-led genetic medicines, while still emphasizing robustness and post-market follow-up. [1]
- Multiple programs highlight the regulatory spectrum in gene therapy and gene editing, from Priority Review acceptance (Ultragenyx) to requests for more rigorous controls (uniQure). [2], [6]
- Access and commercialization continue to expand outside the US, with ELEVIDYS now reimbursed and launched in Japan via a local partner. [3]
- Safety monitoring remains central for systemic gene editing approaches, as shown by the MAGNITUDE hold lift paired with additional exclusions and monitoring. [8]
🗓️ Explore details and sources
- Week 19–25 February 2026
- Week 26 February–4 March 2026
📚 See the full Cell and Gene Therapy archive on our research hub page.
FAQ
What is FDA’s “plausible mechanism” framework meant to do for bespoke therapies?
It is draft guidance describing an approval pathway for individualized genome editing and certain RNA-based approaches in rare diseases, potentially leveraging small patient datasets plus natural history data (criteria-based, high bar noted). [1]
What is the FDA timeline for Ultragenyx’s DTX401 in GSDIa?
FDA accepted the DTX401 BLA with Priority Review and set a PDUFA action date of 23 Aug 2026. [2]
Who can receive ELEVIDYS in Japan, based on the launch announcement?
The release states availability for ambulatory Duchenne muscular dystrophy patients aged 3 to <8, with specific exon 8 and/or 9 deletions and anti-AAVrh74 antibody negativity (additional criteria may apply). [3]
What did Iovance report for lifileucel in UPS and DDLPS?
In a pilot trial, Iovance reported a 50% ORR in the first six evaluable patients and said it plans a single-arm registrational trial with FDA discussions on an expedited path (details not specified). [4]
Why did uniQure say its AMT-130 pathway needs additional work?
FDA stated Phase I/II data versus an external control were not sufficient as primary evidence and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. [6]
What changed for Intellia’s MAGNITUDE Phase 3 in ATTR-CM?
FDA lifted the clinical hold, and Intellia outlined safety mitigation steps including enhanced liver monitoring, steroids guidance, and updated exclusion criteria (including cardiovascular instability and EF <25%). [8]
Entities / Keywords
FDA, CBER, “plausible mechanism” framework, bespoke genetic medicines, genome editing, CRISPR, antisense oligonucleotides (ASOs) [1]
DTX401 (pariglasgene brecaparvovec), Ultragenyx, glycogen storage disease type Ia (GSDIa), BLA, Priority Review, PDUFA [2]
ELEVIDYS (delandistrogene moxeparvovec), Sarepta, Chugai, Roche, Duchenne muscular dystrophy (DMD), NHI reimbursement [3]
Iovance, lifileucel, tumor infiltrating lymphocyte (TIL) therapy, UPS, DDLPS, RECIST v1.1, ORR [4]
GEMMABio (Gemma Biotherapeutics), GB221, CHARISMA, SMA1, rare pediatric disease designation, priority review voucher (PRV) [5]
uniQure, AMT-130, Huntington’s disease, Type A meeting, external control, sham-controlled trial [6]
Ocugen, OCU400, retinitis pigmentosa (RP), liMeliGhT, LDNA, EMA MAA [7]
Intellia, nexiguran ziclumeran (nex-z), ATTR-CM, MAGNITUDE, clinical hold, liver safety monitoring [8]
References
https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-gene-therapies